PP
SCMP

Paloma Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Paloma Partners’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-14,291
Closed -$247K – 2192
2015
Q4 		$247K Buy
+14,291
New +$256K 0.01% 1444

Other funds holding SCMP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Paloma Partners's SCMP Position: Q1 2016 in Review

Paloma Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2016, closing a stake of 14,291 shares — an estimated $247K sold.

Paloma Partners first reported a position in SCMP in Q4 2015 and held it in 1 quarter. The position peaked at $247K in Q4 2015. 134 funds tracked by Wall St. Rank hold SCMP as of Q1 2016.

  • Paloma Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Paloma Partners sold 14,291 Sucampo Pharmaceuticals, Inc. shares in Q1 2016, an estimated $247K.
  • Paloma Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Paloma Partners's Sucampo Pharmaceuticals, Inc. position peaked at $247K in Q4 2015.
  • 134 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2016.

Based on Paloma Partners's 13F filing for Q1 2016, filed 16 May 2016.